Tumor lysis syndrome early after treatment with bortezomib for multiple myeloma

被引：13
作者：
Kenealy, Melita K. [1 ]
Prince, H. Miles [1 ]
Honemann, Dirk [1 ]
机构：
[1] Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne, Vic 3001, Australia
来源：
PHARMACOTHERAPY | 2006年 / 26卷 / 08期
关键词：
bortezomib; tumor lysis syndrome; TLS; multiple myeloma;
D O I：
10.1592/phco.26.8.1205
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1205 / 1206
页数：2
相关论文
共 50 条
  • [1] Tumor lysis syndrome in multiple myeloma treated with bortezomib
    Dhanraj, K. M.
    Biswajit, Dubashi
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2014, 5 (02) : 161 - 162
  • [2] Management of Tumor Lysis Syndrome in Patients With Multiple Myeloma During Bortezomib Treatment
    Wang, Li
    Jian, Yuan
    Yang, Guangzhong
    Gao, Wen
    Wu, Yin
    Zuo, Lihong
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (01) : E4 - E7
  • [3] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Terpos, E
    Politou, M
    Rahemtulla, A
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (10) : 623 - 625
  • [4] Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration
    Evangelos Terpos
    Marianna Politou
    Amin Rahemtulla
    Journal of Cancer Research and Clinical Oncology, 2004, 130 : 623 - 625
  • [5] Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia
    Jaskiewicz, AD
    Herrington, JD
    Wong, L
    PHARMACOTHERAPY, 2005, 25 (12): : 1820 - 1825
  • [6] Rapid complete remission in multiple myeloma with bortezomib/thalidomide/dexamethasone combination therapy following development of tumor lysis syndrome
    C. S. Chim
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 181 - 182
  • [7] Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
    Kondo, Masahiro
    Hotta, Yuji
    Yamauchi, Karen
    Sanagawa, Akimasa
    Komatsu, Hirokazu
    Iida, Shinsuke
    Kimura, Kazunori
    BMC CANCER, 2020, 20 (01)
  • [8] Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study
    Masahiro Kondo
    Yuji Hotta
    Karen Yamauchi
    Akimasa Sanagawa
    Hirokazu Komatsu
    Shinsuke Iida
    Kazunori Kimura
    BMC Cancer, 20
  • [9] High Risk of Tumor Lysis Syndrome in Symptomatic Patients with Multiple Myeloma with Renal Dysfunction Treated with Bortezomib
    Oiwa, Kana
    Morita, Mihoko
    Kishi, Shinji
    Okura, Miyuki
    Tasaki, Toshiki
    Matsuda, Yasufumi
    Tai, Katsunori
    Hosono, Naoko
    Ueda, Takanori
    Yamauchi, Takahiro
    ANTICANCER RESEARCH, 2016, 36 (12) : 6655 - 6662
  • [10] Carfilzomib-Induced Tumor Lysis Syndrome and Biventricular Heart Failure in a Patient With Multiple Myeloma
    Azad, Farhan
    Moyer, Ross
    Miranda, Clive J.
    Gravina, Matthew
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (01)
12345